Applications of Cytarabine in Industrial Manufacturing

As a primary manufacturer of cytarabine, we supply this compound as a high-purity active pharmaceutical ingredient (API) for critical applications across the hematological therapeutic supply chain. Below, we detail key downstream scenarios where cytarabine forms the foundation for advanced formulation and production, each governed by stringent compliance and process controls specific to regulated pharmaceutical pathways.

1. Injectable Antineoplastic Drug Production (Lyophilized and Solution for Injection)

Oncology drug manufacturers use cytarabine as the main chemotherapeutic agent in the formulation of sterile injectable products for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and other hematological malignancies. Sterile fill-finish operations require precisely controlled raw material dispensing and in-process quality controls, matching global pharmacopoeial requirements for finished drug safety and efficacy. Our GMP-certified cytarabine integrates directly into validated aseptic processing suites, supporting batch-specific traceability and reliable bulk packaging formats designed for cGMP environments.

Industry compliance standards

• ICH Q7 and EU GMP Part II for API manufacturing
• United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP) monographs for cytarabine
• FDA 21 CFR Parts 210 & 211 for finished pharmaceuticals
• PIC/S GMP guidelines for injectable drugs

Typical usage ratio

• Formulators use cytarabine at concentrations of 10–100 mg/mL, tailored based on patient dosing regimens; concentration is adjusted according to vial fill size and therapeutic indication.

Downstream process integration

• Weighing and dilution with WFI (Water for Injection) or buffered solutions in Class 100 (ISO 5) cleanrooms, followed by sterile filtration and aseptic filling, then lyophilization or sealed as solution under clean-in-place validated lines.

Final product types

• Lyophilized powder for injection vials
• Prefilled solution for injection vials or ampoules
• Ready-to-use multi-dose bags for hospital oncology compounding units

2. High-Dose Chemotherapy Formulation for CNS Malignancies (Intrathecal Preparation)

Compounding pharmacies and specialty oncology units rely on cytarabine as the API in high-concentration sterile solutions indicated for intrathecal administration targeting leukemia or lymphoma cells in the central nervous system. The formulation must meet specific pH, osmolality, and clear solution criteria, with elevated scrutiny over endotoxin and particulate levels. Our consistent lot-to-lot analytical profile allows for reproducibility in pharmacy compounding, reducing the risk of incompatibility or precipitation during admixture.

Industry compliance standards

• USP Chapter <797> for sterile compounding
• USP and Ph. Eur. monographs for cytarabine (identity, purity, endotoxin levels, particulate matter)
• FDA guidance for intrathecal APIs
• Compounding pharmacy state board regulations or NRDA guidelines (for specific regions)

Typical usage ratio

• Typical compounded concentrations range from 20–100 mg/mL depending on protocol, with single-use doses adjusted based on body surface area and regimen intensity.

Downstream process integration

• Direct weighing and dissolution in sterile, pyrogen-free saline or CSF-similar vehicles in ISO-classified laminar flow hoods, followed by filtration through 0.22-micron sterilizing-grade filters and immediate packaging into single-use syringes for clinical delivery.

Final product types

• Intrathecal sterile syringes
• Ready-to-administer high-dose cytarabine ampoules for CNS treatment centers

3. Ready-to-Dilute Oncology Drug Kits for Hospital Pharmacy Compounding

Hospital and oncology clinics increasingly require cytarabine as pre-measured, unit-dose kits to streamline extemporaneous compounding and reduce medication errors. For this channel, manufacturers assemble GMP-graded cytarabine as API units with diluent and ancillary components, designed to shorten preparation time under pressure in clinical pharmacy settings. We supply the core cytarabine component to centralized packagers, supporting label and traceability requirements under hospital compounding protocols.

Industry compliance standards

• USP <795>, <797> for non-sterile and sterile compounding
• ISO 9001/ISO 13485 for medical device kit assembly
• GMP Part I (EU, WHO) for kit-packaged APIs
• Local jurisdiction hospital labeling safety standards

Typical usage ratio

• Kits contain 50–500 mg of cytarabine per unit, reflecting adult or pediatric protocol needs and hospital inventory turnover rates; final content determined by end-user compounding workflow.

Downstream process integration

• API unit weighing and secondary packaging in ISO-classified areas, in tandem with diluents, transfer devices, and instructions, assembled under in-line pharmaceutical QA and batch record controls.

Final product types

• Ready-to-dilute cytarabine injection kits
• Sterile combination packs for in-hospital pharmacy use

4. Cytarabine-Based Reference Standards for Analytical Laboratories

Analytical reference laboratories require certified cytarabine standards for HPLC, GC, and LC-MS method validation, impurity profiling, and stability studies during drug development, regulatory submissions, and release testing. We manufacture high-purity, traceable reference-grade material with comprehensive CoA and isotopic labeling where required, supporting pharmaceutical QC labs, academic research institutes, and in-house QA teams at finished drug manufacturers.

Industry compliance standards

• ISO/IEC 17025 accreditation (for calibration and testing labs)
• USP/NF and Ph. Eur. reference standard protocols
• FDA and EMA guidelines for analytical method characterization
• OECD GLP principles (for nonclinical test sites)

Typical usage ratio

• Reference standards supplied as 5–100 mg vials; analytical test methods typically employ 0.01–1 mg/mL solutions, adjusted per sensitivity and matrix requirements of the downstream method.

Downstream process integration

• Direct dissolution and dilution in laboratory solvents for use as calibration standards, system suitability testing, and ongoing QC stability monitoring; supports calibration curve generation in regulated environments.

Final product types

• Pharmaceutical reference standard sets
• Research-grade cytarabine analytical standards for drug development
• Stability and process impurity analytical standards